News

BIO-CAT Publishes Foundational Study of Digestive Enzyme Function

TROY, Va.,/PRNewswire/ — A clinical trial designed by BIO-CAT, Inc – a biotech company specializing in enzyme development – studied the use of enzymes to improve digestion in an in vitro model of aging. The results showed that a multi-component supplemental enzyme blend (microbial proteases, lipase, amylase, and glucoamylase) effectively released nutrients from a balanced meal better than control conditions, which solely relied upon endogenous enzymes similar to those already present in the human digestive system. Particularly impressive was the enhanced digestion during the acidic gastric phase, further confirming that the microbial enzymes are naturally acid-tolerant without encapsulation. The peer-reviewed manuscript describing these results is now published in the food science journal, Food Chemistry.

The BIO-CAT R&D team chose the INFOGEST model to adapt for the study of supplemental digestive enzymes. First described in 2014updated in 2019, and cited over 1500 times since, the INFOGEST simulation of human gastrointestinal digestion was developed by the International Network on Food Digestion with over 200 scientists from 32 countries. The INFOGEST protocol models each of salivary, gastric, and intestinal digestion with specific simulated digestion fluids, pH conditions, and enzymes to reflect human digestive physiology.

In a final series of experiments, the BIO-CAT team modified the INFOGEST protocol to model the decline in digestive function that accompanies each of advancing age and antacid use. Under both models of handicapped gastric conditions, the multi-enzyme blend was able to restore and improve macronutrient digestion and nutrient release. Additionally, BIO-CAT is now able to offer tailored INFOGEST testing for customers and partners.

The BIO-CAT publication comes on the heels of another exciting announcement from BIO-CAT. In January, the company initiated a clinical trial of the same multi-enzyme blend specifically in older adults aged 50-70 who may naturally experience changes in digestion. Study outcomes include changes nutrient absorption, gastrointestinal symptoms, and bowel function between the enzyme blend and placebo.

Read more here.

Recent News

06/17/2025

Life Sciences Workforce Collaborative (LSWC) Officially Launches to Strengthen Talent Pipelines Across the U.S.

The Life Sciences Workforce Collaborative (LSWC), a newly launched national nonprofit initiative, formally announced its debut today at the 2025 BIO International Convention. Formerly known as the Coalition of State Bioscience Institutes (CSBI), the LSWC brings together more than 50 state and regional life sciences associations and workforce leaders to scale industry-led solutions to talent development

06/02/2025

Virginia Tech researchers find promise in a new peptide drug to combat a deadly brain cancer

A lab-designed molecule developed and extensively studied by scientists with Virginia Tech’s Fralin Biomedical Research Institute at VTC could represent a breakthrough in slowing tumor recurrence in glioblastoma, an aggressive and deadly form of brain cancer. In a study published May 16 in Cell Death and Disease, researchers identified a previously unknown trait of cancer cells that

05/28/2025

Brandy Salmon named Virginia Tech’s first vice president for innovation and partnerships

Brandy Salmon, who since 2017 has led Virginia Tech teams focused on connecting the university with corporations, foundations, and alumni worldwide has been named the university’s first vice president for innovation and partnerships. “True collaboration between higher education, government, and industry is essential for success in today’s evolving landscape,” said Virginia Tech President Tim Sands.